Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

BACKGROUND: Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor recepto...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Ma, Cheng-Jen, Chang, Tsung-Kun, Tsai, Hsiang-Lin, Su, Wei-Chih, Huang, Ching-Wen, Yeh, Yung-Sung, Chang, Yu-Tang, Wang, Jaw-Yuan
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6923824/
https://ncbi.nlm.nih.gov/pubmed/31856912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-019-3917-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados